陆春风

师资介绍：

陆春风，博士，副教授，硕士生导师。主要从事肝脏疾病病理生理机制及药物防治研究，重点关注细胞代谢重编程与程序性细胞死亡在酒精性肝病、代谢相关脂肪性肝病等疾病进程中的调控作用，并开展相关干预靶标发现及候选药物筛选研究。近年来主持国家自然科学基金青年科学基金项目、江苏省高等学校自然科学研究项目、南通市科技计划项目等科研项目，相关成果发表于Cell Death & Disease、Cell Proliferation、Free Radical Biology and Medicine、Biochemical Pharmacology等期刊，并获授权中国发明专利。

教育经历：

2008.09—2012.06，南京中医药大学，药学专业，获学士学位

2012.09—2017.06，南京中医药大学，中药学专业，获博士学位

工作经历：

2018.05—2022.08，南通大学药学院，讲师

2019.02—2020.02，美国路易斯安那州立大学健康科学中心，博士后

2022.09—至今，南通大学药学院，副教授

研究方向：

肝脏疾病病理生理机制研究

肝脏疾病药物防治及活性成分筛选

社会学术兼职：

南通市药学会药理、药剂分会青年委员

主持基金项目：

国家自然科学基金青年科学基金项目，81803606，川芎嗪通过Sestrin2调控自噬介导的肝细胞程序性坏死防治酒精性肝病的机制研究，2019.01—2021.12，21万元，结题，主持

江苏省高等学校自然科学研究项目，22KJB360015，基于UQCRC2介导自噬探究紫檀芪抑制酒精性肝细胞衰老的机制，2022.07—2024.06，3万元，主持

南通市科技计划项目，MS12018051，Nrf2/HMGB1轴调控细胞程序性坏死在奥沙利铂致肝毒性中的作用及临床意义，2018.07—2020.06，10万元，结题，主持

代表性论文：

Wang Y, Wei W, Zhang Y, Miao J, Bao X*,Lu C*. MLKL as an emerging machinery for modulating organelle dynamics: regulatory mechanisms, pathophysiological significance, and targeted therapeutics.Frontiers in Pharmacology. 2025; 16: 1512968.

Lu C, Zhang Y, Miao J, Wei W, Wang Y, Han Y, Li Y, Tong Y, Wang T, Bao X*. Inhibition of ZFP281/ZNF281-RIPK1/RIPK3/MLKL signaling in hepatocytes by pterostilbene relieves hepatic lipometabolic disorder and inflammation in non-alcoholic steatohepatitis.International Immunopharmacology. 2025; 146: 113936.

Ge T, Wang Y, Han Y, Bao X,Lu C*. Exploring the Updated Roles of Ferroptosis in Liver Diseases: Mechanisms, Regulators, and Therapeutic Implications.Cell Biochemistry and Biophysics. 2025; 83: 1445–1464.

Cai Y, Wang Y, Su W, Zhou X,Lu C*. Angelica sinensis polysaccharide suppresses the Wnt/β-catenin-mediated malignant biological behaviors of breast cancer cells via the miR-3187-3p/PCDH10 axis.Biochemical Pharmacology. 2024; 225: 116295.

Ge T, Shao Y, Bao X, Xu W*,Lu C*. Cellular senescence in liver diseases: From mechanisms to therapies.International Immunopharmacology. 2023; 121: 110522.

Jiang Y#, Zhou Y#, Xu W, Wang X, Jin H, Bao X,Lu C*. Induction of Sestrin2 by pterostilbene suppresses ethanol-triggered hepatocyte senescence by degrading CCN1 via p62-dependent selective autophagy.Cell Biology and Toxicology. 2023; 39(3): 729–749.

Lu C, Jiang Y, Xu W*, Bao X*. Sestrin2: multifaceted functions, molecular basis, and its implications in liver diseases.Cell Death & Disease. 2023; 14(2): 160.

Lu C, Ge T, Shao Y, Cui W, Li Z, Xu W*, Bao X*. ZNF281 drives hepatocyte senescence in alcoholic liver disease by reducing HK2-stabilized PINK1/Parkin-mediated mitophagy.Cell Proliferation. 2023; 56(3): e13378.

Zhou Y, Wu R, Wang X, Bao X,Lu C*. Roles of necroptosis in alcoholic liver disease and hepatic pathogenesis.Cell Proliferation. 2022; 55(3): e13193.

Zhou Y#, Wu R#, Wang X#, Jiang Y#, Xu W, Shao Y, Yue C, Shi W, Jin H, Ge T, Bao X,Lu C*. Activation of UQCRC2-dependent mitophagy by tetramethylpyrazine inhibits MLKL-mediated hepatocyte necroptosis in alcoholic liver disease.Free Radical Biology and Medicine. 2022; 179: 301–316.

Shao Y#, Wang X#, Zhou Y, Jiang Y, Wu R,Lu C*. Pterostilbene attenuates RIPK3-dependent hepatocyte necroptosis in alcoholic liver disease via SIRT2-mediated NFATc4 deacetylation.Toxicology. 2021; 461: 152923.

Wu R#, Wang X#, Shao Y, Jiang Y, Zhou Y,Lu C*. NFATc4 mediates ethanol-triggered hepatocyte senescence.Toxicology Letters. 2021; 350: 10–21.

Zhou Y, Jin H, Wu Y, Chen L, Bao X,Lu C*. Gallic acid protects against ethanol-induced hepatocyte necroptosis via an NRF2-dependent mechanism.Toxicology in Vitro. 2019; 57: 226–232.

授权专利：

陆春风，许文萱，包小峰等，樱草素在制备肝纤维化治疗药物中的应用，中国发明专利，专利号CN116077475B